Ninlaro
Payments companies reported to CMS as associated with Ninlaro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ninlaro, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ninlaro
These are the largest totals companies reported as associated with Ninlaro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hakan Kaya | Spokane, WA | Medical Oncology | $84,344.67 |
| Saulius Girnius | Montgomery, OH | Hematology & Oncology | $48,444.22 |
| Mihir Raval | Albany, NY | Hematology & Oncology | $44,792.23 |
| Daniel Verina | New York, NY | Acute Care (Nurse Practitioner) | $24,534.48 |
| Rajesh Behl | Berkeley, CA | Hematology & Oncology | $20,682.22 |
| Joshua Richter | New York, NY | Medical Oncology | $19,074.40 |
| Moshe Levy | Dallas, TX | Medical Oncology | $18,141.62 |
| Ehsan Malek | Buffalo, NY | Medical Oncology | $12,803.32 |
| Joseph Lynch | Danville, PA | Hematology & Oncology | $10,990.00 |
| Charina Toste | Henderson, NV | Nurse Practitioner | $8,583.14 |
Prescribed Ninlaro?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.